Verve and Lilly Relationship Expands to Include Verve’s In Vivo Gene Editing Programs Targeting PCSK9 and ANGPTL3
31 Ottobre 2023 - 11:01AM
Verve Therapeutics, Inc., a clinical-stage biotechnology
company pioneering a new approach to the care of cardiovascular
disease with single-course gene editing medicines, today announced
the expansion of its relationship with Eli Lilly and Company
(Lilly). Lilly has acquired from Beam Therapeutics certain product
rights to Verve’s cardiovascular in vivo gene editing programs
targeting PCSK9 and ANGPTL3, as well as a third undisclosed
cardiovascular disease (CVD) target. Verve’s PCSK9 product
candidates, VERVE-101 and VERVE-102, and ANGPTL3 product candidate,
VERVE-201, are designed to potently and durably lower low-density
lipoprotein cholesterol throughout the lifetime of patients with or
at risk for atherosclerotic cardiovascular disease (ASCVD), the
most common form of CVD.
For the PCSK9 and ANGPTL3 product candidates, Lilly now holds
the product rights previously held by Beam, including the right to
opt-in to share 33% of worldwide development expenses and to
jointly commercialize and share profits and expenses related to
commercialization in the United States on a 50/50 basis. Verve
holds all product rights for the PCSK9 and ANGPTL3 programs outside
the United States. Under the collaboration agreement, Verve retains
control of the development and commercialization of all
collaboration products. Additionally, Lilly also acquired Beam’s
right to opt-in to co-fund and share in potential profits on
similar terms for a third undisclosed CVD target.
“We are thrilled to gain Lilly as a potential long-term partner
for the next stage of development of our gene editing medicines for
people with ASCVD,” said Sekar Kathiresan, M.D., co-founder and
chief executive officer of Verve. “Lilly brings valuable know-how
in the cardiometabolic space, as well as commercialization
expertise of products for large indications. Lilly’s significant
investment in acquiring Beam’s product rights confirms Lilly’s
confidence in Verve’s programs and the supporting preclinical and
interim clinical data. We continue to be impressed by Lilly’s
commitment to genetic medicines, and their team’s interest in
applying gene editing technology to the cardiometabolic space
closely aligns with Verve’s vision.”
Ruth Gimeno, Ph.D., group vice president, diabetes, obesity and
cardiometabolic research at Lilly, added: “Gene editing is an
exciting new frontier for medicine, potentially allowing durable
efficacy with one-time treatment. Verve is a leader in developing
gene editing therapies for cardiovascular disease, and we are
pleased to expand our relationship with Verve to develop much
needed new treatment options for people with cardiovascular
disease.”
This transaction represents an expansion of the relationship
between Verve and Lilly. Previously, in June 2023, Verve and Lilly
had entered into an exclusive research collaboration focused on
advancing Verve’s preclinical stage in vivo gene editing program
targeting lipoprotein(a).
About Verve Therapeutics Verve
Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage genetic
medicines company pioneering a new approach to the care of
cardiovascular disease, potentially transforming treatment from
chronic management to single-course gene editing medicines. The
company’s initial three programs – VERVE-101, VERVE-102, and
VERVE-201 – target genes that have been extensively validated as
targets for lowering low-density lipoprotein cholesterol (LDL-C), a
root cause of cardiovascular disease, in order to durably reduce
blood LDL-C levels. VERVE-101 and VERVE-102 are designed to
permanently turn off the PCSK9 gene in the liver and are being
developed initially for heterozygous familial hypercholesterolemia
(HeFH) and ultimately to treat atherosclerotic cardiovascular
disease (ASCVD) patients not at goal on oral therapy. VERVE-201 is
designed to permanently turn off the ANGPTL3 gene in the liver and
is initially being developed for homozygous familial
hypercholesterolemia (HoFH) and ultimately to treat patients with
refractory hypercholesterolemia. For more information, please visit
www.VerveTx.com.
Cautionary Note Regarding Forward Looking
StatementsThis press release contains “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995 that involve substantial risks and
uncertainties, including statements regarding the potential
benefits and results that may be achieved through the collaboration
with Lilly; whether Lilly will exercise its opt-in rights with
respect to any of the programs under the collaboration; and the
therapeutic potential of the company’s programs. All statements,
other than statements of historical facts, contained in this press
release, including statements regarding the company’s strategy,
future operations, future financial position, prospects, plans and
objectives of management, are forward-looking statements. The words
“anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,”
“intend,” “may,” “plan,” “potential,” “predict,” “project,”
“should,” “target,” “will,” “would” and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any
forward-looking statements are based on management’s current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in, or implied by,
such forward-looking statements. These risks and uncertainties
include, but are not limited to, risks associated with the
company’s limited operating history; the company’s ability to
timely submit and receive approvals of regulatory applications for
its product candidates; advance its product candidates in clinical
trials; initiate, enroll and complete its ongoing and future
clinical trials on the timeline expected or at all; correctly
estimate the potential patient population and/or market for the
company’s product candidates; replicate in clinical trials positive
results found in preclinical studies and/or earlier-stage clinical
trials of VERVE-101, VERVE-102, and VERVE-201; advance the
development of its product candidates under the timelines it
anticipates in current and future clinical trials; obtain, maintain
or protect intellectual property rights related to its product
candidates; manage expenses; and raise the substantial additional
capital needed to achieve its business objectives. For a discussion
of other risks and uncertainties, and other important factors, any
of which could cause the company’s actual results to differ from
those contained in the forward-looking statements, see the “Risk
Factors” section, as well as discussions of potential risks,
uncertainties and other important factors, in the company’s most
recent filings with the Securities and Exchange Commission and in
other filings that the company makes with the Securities and
Exchange Commission in the future. In addition, the forward-looking
statements included in this press release represent the company’s
views as of the date hereof and should not be relied upon as
representing the company’s views as of any date subsequent to the
date hereof. The company anticipates that subsequent events and
developments will cause the company’s views to change. However,
while the company may elect to update these forward-looking
statements at some point in the future, the company specifically
disclaims any obligation to do so.
Verve Investor Contact:Jen RobinsonVerve
Therapeutics, Inc.jrobinson@vervetx.com
Verve Media ContactAshlea
Kosikowski1ABashlea@1abmedia.com
Grafico Azioni Verve Therapeutics (NASDAQ:VERV)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Verve Therapeutics (NASDAQ:VERV)
Storico
Da Giu 2023 a Giu 2024